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Abstract
With continuously increasing costs of conducting trials, use of innovative approaches—such as pragmatic trials,
registry-based randomised trials, adaptive trials, personalised medicine trials, platform trials, and basket trials—to the
design and conduct of clinical trials has been advocated as one of the most promising solutions. In this editorial,
we propose that the next wave of feasibility or pilot studies should focus on assessing the feasibility of trials using
these designs, which we see as an imperative in order to unleash their potential to reduce trial costs and accelerate
the drug development process and the search for best treatments, so that the right treatments can be delivered as
soon as possible to the right patients.
In this editorial, we welcome Professor Lehana Thabane
as new co-Editor-in-Chief to work alongside Professor
Gillian Lancaster. The journal has seen substantial
growth over the past 18 months and with it the need for
a second Editor-in-Chief. With all articles published in
the journal indexed in PubMed, we look to the future
and consider the next phase in the conduct and
reporting of pilot and feasibility studies; we think
about how innovative trial designs are contributing to
improving trial efficiency.
Pilot and Feasibility Studies was launched in January
2015 to provide a dedicated place for the reporting of
feasibility and pilot studies, and discussion of methodo-
logical issues around the planning, of future large-scale
definitive trials and observational studies [1]. Led by the
Working Group of the CONSORT Extension for Pilot
and Feasibility Trials, the journal was established as
part of the collective effort to change the practice of
reporting of pilot and feasibility studies [2]. These ef-
forts have also led to the publication of a framework
which clarifies the similarities and differences between
a feasibility study and a pilot study. The former asks
whether something can be done, if we should we
proceed with it, and if so, how? In contrast, the latter
asks the same questions, but it also has the specific de-
sign feature that a pilot study is a forerunner of a future
study (or part of a future study) which will be con-
ducted on a larger scale [3].
Then followed the publication of the CONSORT ex-
tension to pilot and feasibility trials, aimed at enhancing
the transparency and completeness of reporting of pilot
and feasibility randomised clinical trials, which are de-
signed to inform the planning of future definitive trials
[4, 5]. The methods and processes used to develop the
CONSORT guideline have been described elsewhere [6].
Since its inception, Pilot and Feasibility Studies has re-
ceived numerous submissions of pilot work, leading to
over 140 publications—with 89 study protocols and 44
research reports of pilot and feasibility studies as the
most frequent types of publication (Table 1). Clearly, the
publication of pilot work in the journal is gaining mo-
mentum. This is also a sign of the growing recognition
of the importance of reporting the design and results of
pilot and feasibility studies.
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With rapidly rising costs of conducting clinical trials
and limited funding [7], there has been some intense de-
bate among stakeholders—funders, sponsors, clinical tri-
alists, consumers and providers—on how to reduce trial
costs. The use of innovative approaches to the design
and conduct of clinical trials has been advocated as one
of the most promising solutions. Examples of these ap-
proaches include pragmatic trials [8], observational trials
[9], registry-based randomised trials [10], cluster rando-
mised trials [11], adaptive trials [12], trials using Bayes-
ian methods [13], small sample, biologically based trials
(e.g. personalised medicine trials) [14], N-of-1 trials [15],
platform trials [16], basket trials [17, 18] and umbrella
trials [18]. In general, these innovations seem intuitively
appealing. For example, registry-based trials—which use
registries as the platform for data collection, rando-
mization, and follow-up [10]—have even been described
as the next disruptive technology in clinical research [19];
the platform trial, whose goal is to find the best treatment
or management for a disease condition by simultaneously
studying multiple treatments, has been characterised as a
vision for the future [16].
Compared to standard clinical trial methodologies,
these innovations offer many advantages. For example,
because of their flexibility and efficiency, adaptive trial
designs [12] offer the potential to cut drug develop-
ment costs by allowing researchers (i) the opportunity
to correct or update incorrect assumptions that were
made at the start of the trial; (ii) to select the most
promising treatment options as early as possible; (iii) to
use emerging information that is external to the trial,
in order to adapt the design; and (iv) the opportunity to
react sooner to surprising results—for efficacy, safety
or futility. These adaptations can shorten the develop-
ment time and consequently speed up the development
process, and lower costs. Another example is the use of
basket trials in oncology [17, 18], which have the ad-
vantage of utilising novel designs that match patients
with different cancer types (“baskets”) that have a rare
genetic mutation, regardless of tumour histology, to a
drug that is expected to work through the mutational
pathway.
However, there remain several uncertainties about
the feasibility of some of these innovations in many
clinical or health care settings. Therefore, assessing the
feasibility and the prevailing uncertainties of the appli-
cations of these state-of-the-art technologies and strate-
gies to clinical trials should be a top priority. These
include feasibility of being able to recruit trial partici-
pants; implementation of intervention elements; assess-
ment of outcomes; and evaluation of the acceptability
and ethics of the designs; among others. As we look
into the future, we can expect the next wave of pilot
and feasibility studies to focus on these uncertainties,
in order that the promise of reducing costs by using in-
novative trial designs can be realised. In fact, we have
already seen a number of examples of pilot trials which
have assessed the feasibility of different aspects of these
designs. These have included the BRAVE pilot trial [20]
which used a pragmatic design to assess the feasibility
of a behavioural activation group therapy in reducing
depressive symptoms and improving quality of life in
patients with depression; a study aiming to determine
the feasibility of using patient/disease registries to re-
cruit subjects for clinical trials [21]; a pilot study using
Bayesian methods in N-of-1 trials to assess the effect of
Amitriptyline to relieve pain in juvenile idiopathic arth-
ritis [15]; to mention only a few.
The application of innovative trial designs has the po-
tential to reduce trial costs and accelerate the drug de-
velopment process and the search for best treatments,
so that the right treatments can be delivered as soon as
possible to the right patients. But for these designs to
have a substantial impact on how we develop new treat-
ment strategies, our approaches have to start with asses-
sing their feasibility, and adopting the right objectives
and outcomes. Success in assessing feasibility will add to
our evolving scientific knowledge base, and to our un-
derstanding of the ecology of patient care and the biol-
ogy of human disease; and it will, hopefully, allow us to
better design these trials to enhance the tailoring of
more treatments to more patients in the future. As we
move into the next phase of the new era in the conduct
and reporting of pilot and feasibility studies, we look for-
ward to continuing to work with the editorial team, to
place Pilot and Feasibility Studies in the forefront of re-
search innovation, and allow it to act as a useful forum
for the dissemination and discussion of pilot or feasibil-
ity studies, particularly those that use innovative trial de-
signs. We should mention that the journal is also a
forum for publishing qualitative work and process evalu-
ation alongside trial design in any pilot work [22]; and
debates on topical issues related to the design, conduct
and reporting of pilot and feasibility studies [23].
Table 1 Type of publications in Pilot and Feasibility Studies since
2015
Article type 2015 2016 2017 (Jan–June) Total
Study protocol 25 45 18 89
Research results 14 20 10 44
Editorial 2 0 0 2
Review 1 1 1 3
Methodology 1 3 1 5
Commentary 0 1 0 1
Letter 0 1 0 1
Update 0 1 0 1
Data from journal website on 13 June 2017
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